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Abstract
Aims/hypothesis The receptor for AGEs (RAGE) is linked to
proinflammatory pathology in a range of tissues. The objec-
tive of this study was to assess the potential modulatory role of
RAGE in diabetic retinopathy.
Methods Diabetes was induced in wild-type (WT) and Rage−/−
mice (also known as Ager−/− mice) using streptozotocin while
non-diabetic control mice received saline. For all groups, blood
glucose, HbA1c and retinal levels of methylglyoxal (MG) were
evaluated up to 24 weeks post diabetes induction. After mice
were killed, retinal glia and microglial activation,
vasopermeability, leucostasis and degenerative microvascula-
ture changes were determined.
Results Retinal expression of RAGE inWT diabetic mice was
increased after 12 weeks ( p<0.01) but not after 24 weeks.
Rage−/− mice showed comparable diabetes but accumulated
less MG and this corresponded to enhanced activity of the
MG-detoxifying enzyme glyoxalase I in their retina when
compared with WT mice. Diabetic Rage−/− mice showed sig-
nificantly less vasopermeability, leucostasis and microglial
activation ( p<0.05–0.001). Rage−/− mice were also protected
against diabetes-related retinal acellular capillary formation
( p<0.001) but not against pericyte loss.
Conclusions/interpretation Rage−/− in diabetic mice is protec-
tive against many retinopathic lesions, especially those related
to innate immune responses. Inhibition of RAGE could be a
therapeutic option to prevent diabetic retinopathy.
Keywords Acellular capillaries . Ager . Diabetic
retinopathy . Glucose . Glyoxalase I . HbA1c . Leakage .
Methylglyoxal . Microglia . Mouse . Rage
Abbreviations
BRB Blood–retina barrier
Col IV Collagen IV
GFAP Glial fibrillary acidic protein
GLO-1 Glyoxalase I
GSH Glutathione
HMGB-1 High-mobility group box-1
MG Methylglyoxal
PRR Pattern-recognition receptor
qPCR Quantitative RT-PCR
RAGE-Fc RAGE-inhibiting fusion protein
RAGE Receptor for AGEs
sRAGE Soluble protein fragment of RAGE
STZ Streptozotocin
TUNEL TdT-mediated dUTP-X nick end labelling
TLR Toll-like receptor
WT Wild-type
Introduction
Diabetic retinopathy is typified by breakdown of the blood–
retina barrier (BRB), loss of capillary pericytes and endothe-
lium, microaneurysm formation, neuronal/glial dysfunction
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and progressive ischaemia in the early (non-proliferative)
stages [1]. The pathogenesis of diabetic retinopathy is com-
plex and while the underpinning mechanism(s) remains ill-
defined, there is strong evidence that inflammation plays an
important role [2]. Even in the early stages of disease inflam-
matory pathology manifests as activation of resident and in-
filtrating immune cells, abnormal expression of pro-
inflammatory cytokines, upregulation of adhesion molecules
and leucostasis in retinal capillaries [2]. This relatively non-
specific and sustained response to diabetes-related cell injury
seems to be driven, at least in part, by microglia and Müller
glia acting as the main resident innate immune cells of the
retina.
Innate immune responses are regulated by pattern-
recognition receptors (PRRs) expressed by immunologically
active cells. PRRs, such as the Toll-like receptors (TLRs),
CD36 and the receptor for AGEs (RAGE), can orchestrate
innate responses such as cytokine release and immune cell
activation [3]. Although the complex interplay of PRRs in
the diabetic retina remains poorly understood there has been
recent attention given to RAGE and its role in diabetic reti-
nopathy [4–6].
Amongst the major ligands for RAGE are high-mobility
group box-1 (HMGB-1), amyloid-β, S100B and AGEs [7],
many of which occur in the diabetic retina [8, 9].
Inflammation-related pathways involving RAGE are active
in retinal endothelial cells [10] and Müller glia [6] and expres-
sion of the receptor is enhanced under diabetic conditions [6].
RAGE signalling evokes extracellular signal-regulated kinase
1/2, mitogen-activated protein kinases and P38, leading to
downstream activation of nuclear factor-κB and induction of
pro-inflammatory cytokines and/or oxidative stress [11].
Furthermore, blockade of RAGE ligand–receptor binding
using a soluble protein fragment (sRAGE) can prevent
Müller glial dysfunction [4] during diabetes and retinal capil-
lary leucostasis in AGE-infused normal mice [12]. A recent
study by Li et al [5] used a RAGE-inhibiting fusion protein
(RAGE-Fc) in diabetic mice and demonstrated a reduced leak-
age of albumin into neural retina, although there was no sig-
nificant change in capillary leucostasis. In mice diabetic for
10 months, RAGE blockade prevented acellular capillary for-
mation but not retinal pericyte loss [5]. The current study
seeks to investigate retinal lesion progression using mice in
which RAGE protein has been deleted and we provide insight
into the role RAGE plays in diabetic retinopathy.
Methods
Diabetes induction in mice The Rage-knockout mouse
(Rage−/−; also known as Ager−/−) was generated on an
SVEV129×C57BL/6 background and backcrossed to
C57BL/6 mice for five generations [13]. Wild-type (WT)
C57BL/6 mice were purchased from Harlan Laboratories
(Bicester, UK) and maintained within the Biological
Research Unit at Queen’s University Belfast.
All experiments conformed to the Principles of Laboratory
Animal Care (National Institutes of Health, Bethesda, MD,
USA) and to the UK Home Office regulations. Diabetes was
induced in male Rage−/− mice and WT mice at 12 weeks of
age using five daily i.p. injections of streptozotocin (STZ)
(Sigma, Gillingham, UK) (50 mg/kg in 0.1 mol/l citrate buffer
pH 4.6) . Control groups received ci t rate buffer.
Hyperglycaemia was confirmed 10 days after injection using
glucometric analysis of tail-prick blood samples (FreeStyle
Lite; Abbott Laboratories, Dublin, Ireland). Non-fasting blood
glucose concentrations >13 mmol/l were considered to indi-
cate diabetes. Blood glucose and weight was monitored bi-
weekly. HbA1c levels were determined using Glyco-Tek
Affinity Column (Helena Biosciences Europe, Gateshead,
UK) whenever mice were killed.
Glyoxalase I activity and methylglyoxal formation in the dia-
betic retina Glyoxalase I (GLO-1) enzymatic activity in retinal
homogenates from the 4-week groups was assayed using pre-
viously published protocols [14]. At 8 and 24 weeks diabetes,
the synthesis and purification of methylglyoxal (MG), as well
as the synthesis of the derivatising agent and the standards for
determination of MG, were prepared according to published
procedures [14]. The concentration of MG was determined in
tissue as nmol/mg and by derivatisation with 1,2-diamino-4,5-
dimethoxybenzene. The protein concentration of the tissue ho-
mogenate was determined by the Bradford assay using BSA as
a standard.
GLO-1 and glutathione immunostaining GLO-1 and glutathi-
one (GSH) immunostaining was assessed using rat anti-GLO-
1 (1:200; Abcam, Cambridge, UK) and rabbit anti-GSH (1:1,
000; Agrisera, Vännäs, Sweden) on frozen retinal sections
(20 μm). The GLO-1 and GSH were visualised using goat
anti-rat antibody labelled with Alexa Fluor 488 and goat
anti-rabbit Alexa Fluor 568 (Invitrogen, Paisley, UK).
Quantitative RT-PCR for WT retina Total RNA of retina was
extracted using RNeasy Mini Kit (Qiagen, UK). The level of
Rage and Glo-1 (Glo1) expression in the retina was examined
using quantitative RT-PCR (qPCR) as previously reported [15].
β-Actin was used as the housekeeping gene. Primer sequences
are listed in electronic supplementary material (ESM) Table 1.
Assessment of the BRB Assessment of the BRB was conduct-
ed in cryosections, by assessing albumin leakage from the
retinal vasculature. The vasculature was visualised using bio-
tinylated isolectin GS-IB4 (Sigma) followed by binding to
streptavidin–Alexa Fluor 488 (Life Technologies, Paisley,
UK). Albumin was localised using a goat anti-mouse albumin
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antibody (Bethyl Laboratories, Montgomery, TX, USA)
followed with anti-goat Alexa Fluor 568 (1:500; Life
Technologies). Vessel or neuropile-localised fluorescence
was visualised by using a Nikon TE EZ-C1 confocal system
(Nikon, Kingston Upon Thames, UK). Using NIS Elements
software (Nikon) a threshold value of 12,000 was set for mea-
suring image intensity/brightness. The area (μm2) of the albu-
min staining was measured with the 12,000 brightness inten-
sity threshold in the retinal sections. Images were taken at
three separate points on the central retina at magnification
×40 and n=5 per group of mice.
Leucostasis in the retinal vasculature Leucostasis in diabetic
mice was assessed after 4 weeks of diabetes using
fluorophore-conjugated concanavalin-A, as described previ-
ously [16]. The retinas were mounted on slides and visualised
using a Nikon TE EZ-C1 confocal system (Nikon). Two z
stacks of the retina for each artery/vein with the capillaries
(central and peripheral) were taken and the total number of
leucocytes in the arteries, veins and capillaries were counted.
Assessment of retinal glia and microglia Microglial cells were
identified using rat anti-mouse F4/80 antigen (1:50; AbD
Serotec, Kidlington, UK) on retinal flat mounts. The state of
microglial activation was ascertained using previously pub-
lished methods [17]. Müller cell activation was assessed by
staining glial fibrillary acidic protein (GFAP) (1:500; Rabbit
anti-GFAP; Dako) on retinal sections from mice that had been
diabetic for 24 weeks.
Analysis of retinal DNA damage DNA damage in the retina
was determined by TdT-mediated dUTP-X nick end labelling
(TUNEL) assay using the In Situ Cell Death Detection Kit
(fluorescein; Roche Applied Science, Penzberg, Germany) ac-
cording to the manufacturer’s instructions [15]. Positive cells
were assessed by image analysis in multiple sections. Images
were taken at three separate points on the central retina at mag-
nification ×40 and presented as the average nuclei in the gan-
glion cell layer. The slides were viewed using epifluorescent
microscopy and analysed using NIS Elements (Nikon).
Quantification of capillary degeneration Retinal flat mounts
were prepared for immunofluorescence evaluation as previ-
ously described [15]. Briefly, retinas were stained with bio-
tinylated isolectin GS-IB4 (Sigma) and rabbit anti-mouse col-
lagen IV (Col IV) (1:50; AbD Serotec) overnight and imaged
using confocal microscopy (Nikon NIS Elements Basic
Research (BR) Version 3.0, TE EZ-C1 confocal system).
Four regions were taken at magnification ×40 in the central
and peripheral retina. Acellular capillaries <1.3 μm were
assessed in this study, as in our previous study [15]. Retinal
pericytes in the various mouse groups were assessed using the
trypsin digest technique as previously described [18].
Graphical presentation and statistical analysis Statistical
analysis and graphical presentation was carried out using
Prism 5.0 software (Prism 5, San Diego, CA, USA). One-
way ANOVA was conducted to compare overall differences
among multiple groups and post hoc comparisons were per-
formed using Tukey’s or Bonferroni’s test. A p value of<0.05
was deemed statistically significant.
Results
Characterisation of diabetes STZ induced a consistent state
of diabetes in experimental mice. Analysis of body weight
revealed a 14% and 37% reduction in WT and Rage−/− dia-
betic mice compared with age-matched non-diabetic controls
at 24 weeks of diabetes (ESM Fig. 1 a, b). HbA1c showed an
approximately twofold increase (at 24 weeks) in diabetic mice
compared with non-diabetic mice ( p<0.001; ESM Fig. 1c).
Blood glucose was significantly increased in the diabetic
mice of both WT and Rage−/− mice at 24 weeks of diabetes
(ESM Fig. 1d).
MG and its detoxification in the diabetic retina Compared
with non-diabetic WT controls, Rage mRNA expression in
the retina was increased after 12 weeks of diabetes ( p<0.01)
but this differential was not apparent at 24 weeks (ESMFig. 2).
Since AGEs are key ligands for RAGE in the diabetic retina [9]
and MG-derived adducts are the most abundant in this tissue
during diabetes [19], we examined the accumulation of the
reactive AGE precursor MG in the retina and also the activity
of its detoxifying enzyme GLO-1. Examination of retinal ho-
mogenates showed that after both 8 and 24 weeks of diabetes,
WT diabetic mice had significantly higher levels of MG in the
retina compared with non-diabetic controls; this elevation was
not apparent in Rage−/− diabetic mice (Fig. 1 a, b).
Retinal GLO-1 enzymatic activity and mRNA expression
for different durations of diabetes was examined. At 4 weeks,
retinal GLO-1 activity was significantly enhanced in Rage−/−
mice, irrespective of the presence of diabetes (Fig. 2a). Not
only was GLO-1 activity increased, but also immunofluores-
cent staining suggested that the expression level of GLO-1
was increased at 8 weeks in Rage−/− mouse retinas (Fig. 2b).
The transcript of Glo-1 was also increased significantly at
12 weeks in Rage−/− mouse retinas (Fig. 2c).
Since reduced GSH is required as a co-factor for GLO-1
during detoxification of MG [20], we examined the level of
reduced GSH in the retinas. Immunofluorescent staining re-
vealed that reduced GSH occurred at higher levels in the retina
of Rage−/− mice when compared with WT counterparts, irre-
spective of the presence of diabetes (ESM Fig. 3).
Rage deletion protects against retinal vasopermeability
Vasopermeability was assessed 4 weeks after the induction
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of diabetes. This time point was chosen since a significant break-
down of the inner BRB in parallel with capillary leucostasis has
been shown in this acute phase [21, 22]. Vasopermeability was
assessed through visualisation of albumin that had extravasated
and was localised in the neural retina. Albumin remained local-
ised to the vessel lumens of the retinal circulation and beneath
the retinal pigment epithelium in non-diabetic WT mice
(Fig. 3a). In contrast to their non-diabetic counterparts, diabetic
WT mice showed significantly greater areas of focal leakage
( p<0.01) (Fig. 3 a, b). Diabetic Rage−/− mice appeared to be
protected against albumin leakage into the neural retina since
there was no significant difference in area of leakage compared
with non-diabetic Rage−/− mice (Fig. 3b).
Regu l a t o r y ro l e o f RAGE in re t i na l va s cu l a r
leucostasis Leucostasis is one of the earliest features in murine
diabetic retina and can be detected from as early as 1 week after
diabetes induction, persisting for at least 3 months [23]. We
studied leucostasis after 4 weeks of diabetes using
Concanavalin A–FITC to visualise ‘sticking’ leucocytes inside
blood vessels. There was a significant increase in the number
of adherent leucocytes in the WT diabetic retina (a response
that was apparent for arteries, veins and capillaries) when com-
pared with WT non-diabetic controls ( p<0.05) (Fig. 4a).
Diabetic Rage−/−mice showed a significant reduction in adher-
ent leucocytes compared with diabetic WT mice (Fig. 4 a, b).
Rage deletion attenuates diabetes-related glial and neuronal
dysfunction Glial responses were evaluated using the stress-
indicator GFAP. In the non-diabetic mouse retina, GFAP was
limited in the astrocytes and end feet of Müller cells (Fig. 5a).
In diabetic mice GFAP could be detected in the cell processes
of Müller cells, indicating Müller cell activation or damage.
Rage−/− diabetic mice did not show this typical upregulation
of GFAP in the Müller cells (Fig. 5a).
TUNEL-positive cells, indicatingDNA strand breaks, were
significantly more abundant in the diabetic mice than in non-
diabetic controls ( p<0.001) (Fig. 5b). TUNEL-positive cells
were mainly localised to the ganglion cell layer but they were
also present in the inner and outer nuclear layers. In Rage−/−
Fig. 1 Accumulation of MG-derived adducts in diabetic mouse retina.
MG levels were increased in the retina after both 8 (a) and 24 (b) weeks of
diabetes in WT mice. Levels were determined as nmol/mg and presented
as a percentage of control. Data are expressed as mean ± SEM (n=3 per
group). *p<0.05, **p<0.01 and ***p<0.001 for indicated comparisons
Fig. 2 GLO-1 enzymatic activity in diabetic mouse retina. (a) GLO-1
enzymatic activity is shown in arbitrary units (AU)/mg × 10 min. (b)
GLO-1 immunoreactivity was elevated in non-diabetic Rage−/− and dia-
betic Rage−/− mouse retina compared with the low expression in WT
control and WT diabetic mouse retina. (c) Retinal Glo-1 mRNA expres-
sion (normalised vs β-actin) in WT diabetic mouse retina was lower than
in the WT control and expression in Rage−/− control mouse retina was
higher. Data are expressed as mean ± SEM (n=5 per group). **p<0.01
and ***p<0.001 for the indicated comparisons
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mice, diabetic conditions also increased the number of
TUNEL-positive cells, especially in the ganglion cell layer
( p<0.01) (Fig. 5b). However, comparison between the WT
and Rage−/− diabetic mice showed that the absence of RAGE
significantly protected the diabetic retina against DNA breaks
( p<0.05) (Fig. 5b).
RAGE plays a role in microglial activation during diabetic
retinopathy An increase in microglial activation and number
of cells in the neuropile has been previously demonstrated in
diabetic retinopathy [24]. Following both 12 and 24 weeks
diabetes duration in WTmice, there was a significant increase
in the numbers of F4/80-positive microglia in the retina when
compared with non-diabetic controls ( p<0.001) (Fig. 6a).
Rage−/− mice did not demonstrate this diabetes-induced in-
crease and, indeed, there were significantly less positive mi-
croglia in the retinas of Rage−/− diabetic mice compared with
WT diabetic mice ( p<0.001) (Fig. 6a).
Microglia presented in various states of activation in nor-
mal retina from both WT and Rage−/− mice; however, the
‘classical’ resting (ramified/dendritic; Fig. 6b) state was pre-
dominant (Fig. 6 b, c). Following 12 weeks of diabetes, there
was a significant increase in activated microglia in the WT
diabetic retina whereas this increase was absent in Rage−/−
mice (Fig. 6c). After 24 weeks of diabetes, there was no
apparent increase in microglial activation compared with
non-diabetic controls, only an increase in resting microglia
between WT control and WT diabetic (Fig. 6d).
RAGE deletion protects against diabetes-mediated retinal
capillary degeneration Acellular capillary formation and the
death of pericytes and endothelium in the retina is a hallmark
in mice beyond 5 months of diabetes [25]. By definition, acel-
lular capillaries do not have endothelial cells and the vessels
are isolectin B4 negative but since a basement membrane
persists in these acellular vessels, Col IV immunoreactivity
remains present (Fig. 7a, b). When retinal flat mounts were
Fig. 4 Role of Rage deletion in retinal vascular leucostasis during dia-
betes. (a) Leucostasis was assessed in the mouse retina after 4 weeks of
diabetes covering 0.1 mm2 as the mean of 16 z stacks per retina. Data are
expressed as mean ± SEM (n=6). *p<0.05 for indicated comparison.
Leucocytes are shown: at the branches in the vein of aWT diabetic mouse
retina (b); in the capillaries of a WT diabetic mouse retina (c); at the
junctions of the capillaries of a WT diabetic mouse retina (d) and in the
vein of a Rage−/− diabetic mouse retina (e). Scale bar, 50 μm
Fig. 3 Vasopermeability in diabetic mouse retina is modulated by Rage.
(a) Blood vessel leakage was assessed by albumin (red) staining after
4 weeks of diabetes. There was a significant increase in albumin that
had leaked from the blood vessels (stained green with isolectin B4) in
WT diabetic mice compared with the control WT mice (white arrow
showing leakage). (b) Graph of albumin leakage (area in μm2) from the
retinal blood vessels of Rage−/− diabetic mice showed a decrease in the
amount of leakage compared with that in WT diabetic mice. Data are
expressed as mean ± SEM (n=6). *p<0.05 and **p<0.01 for the indi-
cated comparisons
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evaluated and quantified for isolectin/Col IV staining, there
was a significant increase in acellular capillaries in WT dia-
betic mice compared with non-diabetic controls ( p<0.001)
(Fig. 7c). This diabetes-mediated pathology was absent in
the retina from Rage−/− diabetic mice. In trypsin-digested
preparations, the number of pericytes in the retinal capillaries
Fig. 5 Rage deletion alters GFAP
expression in retinal Müller glia
and DNA strand breaks in
ganglion cells. (a)
Immunostaining of GFAP and
graph showing the mean GFAP-
positive fibres crossing the inner
plexiform layer (IPL) and the
inner nuclear layer (INL) in the
cohort. The red dotted line
indicates the border between the
IPL and the INLwhere the GFAP-
positive fibres cross. ONL, outer
nuclear layer. (b) TUNEL
positivity was assessed on the
sections of retina from all the
experimental groups. GCL,
ganglion cell layer. Scale bar,
50 μm. Data are expressed as
mean ± SEM (n=4). *p<0.05,
**p<0.01 and ***p<0.001 for
indicated comparisons
Fig. 6 Microgliosis in mouse
retinas at 12 and 24 weeks of
diabetes. (a) Total microglia cell
numbers at 12 and 24 weeks of
diabetes illustrating more
microglia in the WT diabetic
mouse than in the other groups.
Ctl, control; Dia, diabetic. (b)
Representative images of
dendritic (resting) and amoeboid
(active) microglia, taken from
Rage−/− control groups. Scale bar,
25 μm. (c, d) Activation states of
microglia were ascertained, post
image capture. These graphs
illustrate activated (black bars)
and resting microglia (white bars)
labelled with F4/80 after 12 and
24 weeks of diabetes. Data are
expressed as mean ± SEM (n=6).
*p<0.05 and ***p<0.001 for
indicated comparisons
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was significantly reduced in diabetic WTmice compared with
controls. Pericyte loss was also significant in the Rage−/− dia-
betic mice (Fig. 7d).
Discussion
RAGE plays a significant role in inflammation-linked disor-
ders such as Alzheimer’s disease and atherosclerosis [26, 27].
In the context of diabetic complications, activation of RAGE
by a range of ligands has been strongly associated with
inflammatory pathology in the kidney and peripheral
nerves and vessels [28]. In the current investigation,
we show that Rage−/− mice are protected from some
of the key early-stage lesions of diabetic retinopathy.
Rage deletion had no significant impact on glycaemia
(based on HbA1c) or characteristic deficits in weight gain.
However, diabetes did increase RAGE expression in the mu-
rine retina after 12 weeks of diabetes, although this elevation
was not maintained up to 24 weeks. RAGE expression is
widespread in the retinal neuropile of rats and mice, being
especially high in the Müller glia [4], and it has been shown
to increase in diabetic rats concomitantly with ligands such as
AGEs and S100b [6, 29].
AGEs are ligands for RAGE and many are derived
from the α-oxoaldehyde MG, which occurs at high
levels in the diabetic retina and gives rise to adducts
such as Nε-(carboxy-ethyl) lysine and MG-derived
hydroimidazolone-1 [30]. An important defence against
MG-related toxicity is the glyoxalase complex (formed from
GLO-1 and glyoxalase II components), which converts MG to
D-lactate using GSH as a co-factor [31]. We have previously
reported that overexpression of GLO-1 in diabetic rats protects
against retinopathy [30]. The current study now shows that
Rage−/− mice possess significantly enhanced retinal GLO-1
activity, a higher GLO-1 expression level and enhanced GSH
levels when compared with WT mice. This explains the re-
duced levels of MG in Rage−/− diabetic mice compared with
their WT diabetic counterparts. The relationship between
RAGE and GLO-1 during diabetes has been reported previ-
ously [32, 33] and it has been suggested that upregulation of
the enzyme is linked to RAGE-mediated transcriptional acti-
vation of Myd88 [34]. In the current study we have demon-
strated that Rage−/− mice have higher levels of retinal GSH
than their WT counterparts and this may also account for
why GLO-1 activity is also elevated in these mice.
Interactions between circulating immune cells and the ret-
inal vasculature probably begin with leucostasis, which may
contribute to capillary occlusion and breakdown of the BRB
[35]. An earlier study suggested that neutrophils become less
sticky after treatment with RAGE antibody [36]. It is possible
that leucocytes from Rage−/− diabetic mice are less sticky due
to the absence of this receptor. Deletion of Rage in diabetic
Fig. 7 Retinal capillary degeneration and pericyte dropout during diabe-
tes after 24 weeks of diabetes. Flat-mounted retina from WT control and
diabetic mice in the deeper plexus (a) and the superficial plexus (b),
illustrating capillaries visualised using isolectin B4 (endothelium; green)
and Col IV (basement membrane; red). Acellular capillaries show con-
tinuance of Col IV positivity but loss of endothelium (arrow). Scale bar,
50 μm. (c) Graph showing the mean number of acellular capillaries in the
retina. Data are expressed as mean ± SEM (n=6). ***p<0.001 for the
indicated comparisons. (d) Graph showing pericyte coverage in the ret-
ina. Data expressed as mean ± SD (n=7). ***p<0.001 for the indicated
comparisons
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mice provided protection against vascular leucostasis and
vasopermeability and this agrees with the findings of previous
studies that used therapeutic approaches. For example, reduc-
ing the bioavailability of RAGE ligands (using sRAGE)
prevented vasopermeability in mice [12]. Deletion of Rage
transcription resulted in a marked protection against adhesion
of leucocytes. While it is uncertain whether the acute-phase
leucostasis phenomenon is a major contributor to capillary
degeneration [37], it seems likely that pro-inflammatory pro-
cesses involving bone marrow-derived cells make a contribu-
tion to diabetic retinopathy [38]. Although not evaluated in the
current study, there is evidence that TLRs may be involved in
retinopathy [39]. The established interplay between TLRs and
RAGE is potentially important and could contribute to innate
immune responses in the retina, especially since they share
common ligand interactions with S100 and HMGB1 [10].
Müller glia act as inflammatory activators and this response
is diminished by sRAGE treatment in db/db mice [4] and, as
shown in the current study, genetic deletion of Rage.
Professional immune cells, which reside in proximity to reti-
nal blood vessels (perivascular macrophages) or within vari-
ous layers of the neuropile (microglia), are of even more crit-
ical importance [40]. While these cells have a homeostatic
function, they are also linked to neuroinflammation in the
human diabetic retina [24] and animal models [41, 42].
RAGE plays a role in monocyte migration and microglial
activation [43, 44] by altering the expression of adhesion mol-
ecules, facilitating monocytic extravasation into the CNS and
altering microglial cells from resting to activated states [45].
The current study suggests a role for RAGE in microglial
activation, especially after 12 weeks of diabetes at which time
Rage−/−mice were protected from this response. This bimodal
response according to the duration of diabetes may also reflect
the altered expression levels of RAGE between 12 and
24 weeks. Further supporting evidence comes from Rage−/−
mice subjected to laser-induced choroidal neovascularisation;
these mice showed reduced lesion size alongside diminution
of immune cell activation when compared with WT controls
[46].
In rodent models of diabetic retinopathy, pericyte dropout
and acellular capillary formation are ‘gold standard’ markers
of retinopathy progression. In the current study, analysis using
both trypsin digests and confocal microscopy of whole
mounts showed significant vasodegeneration at 24 weeks in
WT diabetic mice. Rage−/− mice were protected from
diabetes-induced acellular capillary formation, providing
strong evidence of an important role for this receptor in dia-
betic retinopathy. The fact that pericyte loss was not markedly
prevented when RAGE was absent is in keeping with studies
using RAGE blockade [38] and suggests that loss of these
cells is not strongly associated with the RAGE pathway. Our
data support the suggestion that inflammatory cascades are
linked to retinal vascular damage as diabetes progresses. As
a component of the innate immune response, RAGE plays an
important role in diabetic retinopathy.
Acknowledgements The authors acknowledge generous grant support
from Fight for Sight, Diabetes UK and JDRF. AWS holds a Wolfson
Royal Society Merit Award. HPH was supported by grants from the
EFSD, the German Diabetes Association and the Deutsche
Forschungsgemeinschaft. We would like to dedicate this paper to our
colleague Dr Angelika Bierhaus who sadly passed away while this study
was being conducted.
Contribution statement CMV was involved with the conception and
design of experiments, researched data and wrote the manuscript. MW,
LMC, JGF TF, AS and MK researched data and contributed to the man-
uscript. AB provided Rage−/− mice. HPH was involved with the concep-
tion and design of some experiments and contributed to the manuscript.
MC researched and interpreted data and wrote some of the manuscript.
AWS conceived and designed experiments, interpreted data, wrote the
manuscript and guided the project. All authors revised the paper for im-
portant intellectual content and approved the final version.
AWS is the guarantor of this work and, as such, has full access to all
data in the study and takes responsibility for the integrity of data and
accuracy of the data analysis.
Duality of interest The authors declare that there is no duality of inter-
est associated with this manuscript.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Stitt AW, Lois N, Medina RJ, Adamson P, Curtis TM (2013)
Advances in our understanding of diabetic retinopathy.
Clin Sci (Lond) 125:1–17
2. Tang J, Kern TS (2011) Inflammation in diabetic retinopathy.
Prog Retin Eye Res 30:343–358
3. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflam-
mation. Cell 140:805–820
4. Barile GR, Pachydaki SI, Tari SR et al (2005) The RAGE axis in
early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916–2924
5. Li G, Tang J, Du Y, Lee CA, Kern TS (2011) Beneficial effects of a
novel RAGE inhibitor on early diabetic retinopathy and tactile
allodynia. Mol Vis 17:3156–3165
6. Zong H, Ward M, Madden A et al (2010) Hyperglycaemia-induced
pro-inflammatory responses by retinal Muller glia are regulated by
the receptor for advanced glycation end-products (RAGE).
Diabetologia 53:2656–2666
7. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA (2011) RAGE
biology, atherosclerosis and diabetes. Clin Sci (Lond) 121:43–55
8. Chen M, Curtis TM, Stitt AW (2013) Advanced glycation end prod-
ucts and diabetic retinopathy. Curr Med Chem 20:3234–3240
9. Zong H, Ward M, Stitt AW (2011) AGEs, RAGE, and diabetic reti-
nopathy. Curr Diab Rep 11:244–252
10. Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M,
Abu El-Asrar AM (2013) High-mobility group box-1 protein acti-
vates inflammatory signaling pathway components and disrupts ret-
inal vascular-barrier in the diabetic retina. Exp Eye Res 107:101–109
1136 Diabetologia (2015) 58:1129–1137
11. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP (2005)
Advanced glycation end product receptor-mediated cellular dysfunc-
tion. Ann N YAcad Sci 1043:676–680
12. Moore TC, Moore JE, Kaji Y et al (2003) The role of advanced
glycation end products in retinal microvascular leukostasis.
Invest Ophthalmol Vis Sci 44:4457–4464
13. Constien R, Forde A, Liliensiek B et al (2001) Characterization of a
novel EGFP reporter mouse to monitor Cre recombination as dem-
onstrated by a Tie2 Cre mouse line. Genesis 30:36–44
14. McLellan AC, Phillips SA, Thornalley PJ (1992) The assay of
methylglyoxal in biological systems by derivatization with 1,2-
diamino-4,5-dimethoxybenzene. Anal Biochem 206:17–23
15. McVicar CM, Hamilton R, Colhoun LM et al (2011) Intervention
with an erythropoietin-derived peptide protects against neuroglial
and vascular degeneration during diabetic retinopathy. Diabetes 60:
2995–3005
16. Chen Y, Hu Y, Moiseyev G, Zhou KK, Chen D, Ma JX (2009)
Photoreceptor degeneration and retinal inflammation induced by
very low-density lipoprotein receptor deficiency. Microvasc Res 78:
119–127
17. Pannasch U, Farber K, Nolte C et al (2006) The potassium chan-
nels Kv1.5 and Kv1.3 modulate distinct functions of microglia.
Mol Cell Neurosci 33:401–411
18. Dietrich N, Hammes HP (2012) Retinal digest preparation: a method
to study diabetic retinopathy. Methods Mol Biol 933:291–302
19. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ (2003)
Accumulation of fructosyl-lysine and advanced glycation end prod-
ucts in the kidney, retina and peripheral nerve of streptozotocin-
induced diabetic rats. Biochem Soc Trans 31:1423–1425
20. Thornalley PJ (1998) Glutathione-dependent detoxification of alpha-
oxoaldehydes by the glyoxalase system: involvement in disease
mechanisms and antiproliferative activity of glyoxalase I inhibitors.
Chem Biol Interact 111–112:137–151
21. QaumT, Xu Q, Joussen AM et al (2001) VEGF-initiated blood-retinal
barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:
2408–2413
22. Joussen AM, Poulaki V, Tsujikawa A et al (2002) Suppression of
diabetic retinopathy with angiopoietin-1. Am J Pathol 160:1683–
1693
23. Ishida S, Usui T, Yamashiro K et al (2003) VEGF164 is proinflam-
matory in the diabetic retina. Invest Ophthalmol Vis Sci 44:2155–
2162
24. Zeng HY, GreenWR, TsoMO (2008)Microglial activation in human
diabetic retinopathy. Arch Ophthalmol 126:227–232
25. Zheng L, Du Y, Miller C et al (2007) Critical role of inducible nitric
oxide synthase in degeneration of retinal capillaries in mice with
streptozotocin-induced diabetes. Diabetologia 50:1987–1996
26. RamasamyR, Yan SF, Schmidt AM (2009) RAGE: therapeutic target
and biomarker of the inflammatory response—the evidence mounts.
J Leukoc Biol 86:505–512
27. Sorci G, Riuzzi F, Giambanco I, Donato R (2013) RAGE in tissue
homeostasis, repair and regeneration. Biochim Biophys Acta 1833:
101–109
28. Ramasamy R, Yan SF, Schmidt AM (2012) The diverse ligand rep-
ertoire of the receptor for advanced glycation endproducts and path-
ways to the complications of diabetes. Vasc Pharmacol 57:160–167
29. Curtis TM, Hamilton R, Yong PH et al (2011) Muller glial dysfunc-
tion during diabetic retinopathy in rats is linked to accumulation of
advanced glycation end-products and advanced lipoxidation end-
products. Diabetologia 54:690–698
30. Berner AK, Brouwers O, Pringle R et al (2012) Protection against
methylglyoxal-derived AGEs by regulation of glyoxalase I prevents
retinal neuroglial and vasodegenerative pathology. Diabetologia 55:
845–854
31. Kuhla B, LuthHJ, Haferburg D, BoeckK,Arendt T,Munch G (2005)
Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s dis-
ease. Ann N YAcad Sci 1043:211–216
32. Wu F, Feng JZ, Qiu YH et al (2013) Activation of receptor for ad-
vanced glycation end products contributes to aortic remodeling and
endothelial dysfunction in sinoaortic denervated rats. Atherosclerosis
229:287–294
33. Yao D, Brownlee M (2010) Hyperglycemia-induced reactive oxygen
species increase expression of the receptor for advanced glycation
end products (RAGE) and RAGE ligands. Diabetes 59:249–255
34. Zeng S, Zhang QY, Huang J et al (2012) Opposing roles of RAGE
and Myd88 signaling in extensive liver resection. FASEB J 26:882–
893
35. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM (2007)
Leukocytes in diabetic retinopathy. Curr Diabetes Rev 3:3–14
36. Toure F, Zahm JM, Garnotel R et al (2008) Receptor for advanced
glycation end-products (RAGE) modulates neutrophil adhesion and
migration on glycoxidated extracellular matrix. Biochem J 416:255–
261
37. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS (2008) 5-
Lipoxygenase, but not 12/15-lipoxygenase, contributes to degenera-
tion of retinal capillaries in a mouse model of diabetic retinopathy.
Diabetes 57:1387–1393
38. Li G, Veenstra AA, Talahalli RR et al (2012) Marrow-derived cells
regulate the development of early diabetic retinopathy and tactile
allodynia in mice. Diabetes 61:3294–3303
39. Fujimoto T, Sonoda KH, Hijioka K et al (2010) Choroidal neovascu-
larization enhanced by Chlamydia pneumoniae via Toll-like receptor
2 in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 51:
4694–4702
40. Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging
retina. Prog Retin Eye Res 28:348–368
41. Barber AJ, Antonetti DA, Kern TS et al (2005) The Ins2Akita
mouse as a model of early retinal complications in diabetes.
Invest Ophthalmol Vis Sci 46:2210–2218
42. Rungger-Brandle E, Dosso AA, Leuenberger PM (2000)
Glial reactivity, an early feature of diabetic retinopathy.
Invest Ophthalmol Vis Sci 41:1971–1980
43. Hughes EH, Schlichtenbrede FC, Murphy CC et al (2004)
Minocycline delays photoreceptor death in the rds mouse through a
microglia-independent mechanism. Exp Eye Res 78:1077–1084
44. Bianchi R, Kastrisianaki E, Giambanco I, Donato R (2011) S100B
protein stimulates microglia migration via RAGE-dependent up-reg-
ulation of chemokine expression and release. J Biol Chem 286:7214–
7226
45. Giri R, Shen Y, Stins M et al (2000) beta-amyloid-induced migration
of monocytes across human brain endothelial cells involves RAGE
and PECAM-1. Am J Physiol Cell Physiol 279:C1772–C1781
46. Chen M, Glenn JV, Dasari S et al (2014) RAGE regulates immune
cell infiltration and angiogenesis in choroidal neovascularization.
PLoS One 26:e89548
Diabetologia (2015) 58:1129–1137 1137
